Weight loss jabs could be key to controlling asthma in thousands of Brits, say scientists
Click to share on Facebook (Opens in new window)
WEIGHT loss jabs could help control asthma symptoms in obese people, a study suggests - and it's not just about losing weight.
The drugs should be explored as a potential treatment for obese people with asthma, who are "often resistant" to steroids, researchers said.
Sign up for Scottish Sun
newsletter
Sign up
1
Asthmatic people who used weight loss jabs had less severe symptoms - even if they didn't lose much weight
Credit: Getty
Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicking the hormone GLP-1 to regulate blood sugar and insulin levels and dull hunger pangs.
They were initially developed as a treatment for people with type 2 diabetes - Ozempic is a key example.
Several types of the drug are recommended to help tackle obesity on the NHS, including Wegovy or Mounjaro.
Previous studies have suggested the drugs may slash the risk of illnesses like sleep apnoea, dementia and stroke.
Now, an international team of experts are exploring their potential impact on obese people with asthma.
Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: "People with obesity and asthma are unique in that they are often resistant to steroid treatments.
"We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids."
People with a BMI of 30 or more have a much higher risk of having asthma than those with a lower BMI, according to the American Lung Association.
It said extra weight around the chest and abdomen can constrict the lungs and make it more difficult to breathe.
But research also suggests that fat tissue produces inflammatory substances that might affect the lungs and up the risk of asthma.
Early Warning Signs of an Asthma Attack
Having asthma can also increase the risk of obesity, as symptoms can make it harder to be physically active and long-term steroid use can increase hunger, NHS Cambridge University Hospitals Trust suggests.
For the new study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs.
After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control.
Researchers said the findings suggest medics "should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases".
Prof Price added: "We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms.
"In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year.
WHO IS ELIGIBLE FOR WEIGHT LOSS JABS ON THE NHS?
NHS eligibility for weight loss injections has expanded but still lags behind the number who could potentially benefit from taking them.
Wegovy, medical name semaglutide, is only available for weight loss through specialist weight management clinics.
Patients are typically expected to have tried other weight loss methods before getting a prescription.
They may be eligible if their body mass index (BMI) is higher than 30, or higher than 27 if they have a weight-related health condition such as high blood pressure.
Mounjaro, known as tirzepatide, is also available from GP practices but currently only to patients with a BMI of 40 or higher (or 37.5 if from a minority ethnic background) plus four weight-related health conditions.
The medicines are currently being rationed to the patients most in need.
NHS watchdog NICE estimates that more than three million Brits will ultimately be eligible.
The GLP-1 injections are prescribed separately by GPs for people with type 2 diabetes, and patients should discuss this with their doctor.
"Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further."
Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: "Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs."
Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: "Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs.
"Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening.
"Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative.
"It's too early to say whether these drugs would be effective for people with asthma more widely.
"More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment."
It's though that 7.2 million people in the UK have asthma, according to Asthma + Lung UK.
Meanwhile, 64 per cent of adults aged 18 and above in England were estimated to be overweight or living with obesity between 2023 and 2024.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Record
an hour ago
- Daily Record
GP who wrote prescriptions for dead patients could be struck off as hearing set
John Henderson is due to go before the Medical Practitioners Tribunal Service (MPTS) after he faked prescriptions to administer powerful painkillers to himself. A disgraced doctor who wrote prescriptions in the names of dead patients for self-medication is due to face a professional tribunal that could see him struck off. John Henderson will go before the Medical Practitioners Tribunal Service (MPTS) on Monday, August 4, to determine whether his registration as a GP should be suspended or revoked following his conviction for obtaining prescription drugs by fraud. The 40-year-old was sentenced at Hamilton Sheriff Court last year after admitting to writing out prescriptions for powerful painkillers in his own name — and in the names of former patients, some of whom were deceased. Between July 2021 and February 2022, Henderson either collected the drugs himself from pharmacies or instructed NHS staff to pick them up and bring them to him. The shocking abuse of trust happened across Glasgow and Lanarkshire, involving multiple pharmacies and prescription forms. Henderson, who held a senior position with NHS Lanarkshire, claimed he suffered pain from a gall bladder condition and stress from working long night shifts during the pandemic. He escaped a prison sentence and was handed a community payback order including nine months of supervision and 100 hours of unpaid work to be completed within 12 months. He was also ordered to repay £883.02 in compensation. Now, the MPTS will assess whether Dr Henderson's fitness to practise has been impaired by his criminal behaviour, which involved serious breaches. According to pre-hearing documents, the tribunal will hear evidence that Dr Henderson 'presented the prescriptions to pharmacies, or instructed NHS staff to present them on his behalf and return the medication to him, thus obtaining the medication by fraud.' It was previously heard how NHS counter fraud became concerned about the out of hours GP who was suspected of prescribing drugs for himself. Investigations then uncovered a pattern of prescriptions being made for a strong painkiller called Oxycodone. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you're curious, you can read our Privacy Notice. Investigators linked the paperwork to Henderson and NHS delivery drivers later said they had been asked to make unusual collections from pharmacies on his instruction. In June 2022 a search of his home found needles and drugs and he was arrested. Henderson's lawyer said in court he was deeply sorry for his actions which had been driven by stress and medical issues. The father-of-two has since been living in England with his family. NHS Lanarkshire previously confirmed that immediate steps were taken when the allegations first came to light, including reporting the matter to police and working with relevant medical authorities. If the tribunal finds his actions amount to serious professional misconduct, Dr Henderson could be suspended or struck off the medical register entirely. The MPTS hearing is expected to take place from August 4 to 12.
Telegraph
an hour ago
- Telegraph
Millions on NHS waiting lists yet to have first appointment
Millions of people in England on NHS waiting lists are yet to have their first appointment, new data reveal. Figures from NHS England last month suggest nearly half of those waiting for hospital care have not had their first appointment with a specialist or a diagnostic test since their GP referral. An analysis by health data specialist MBI Health suggests nearly three million out of the 6.23 million patients (48 per cent) waiting for treatment are left in limbo. Experts referred to the issue as a 'frontlog' and warned the crisis 'has gone unchallenged for too long'. MBI's analysis also found that around 70 per cent of referral-to-treatment pathways fall into the category of being 'unseen' since the patient's GP referred them to a specialist. Delays in making a first assessment can lead to late diagnosis, worsening symptoms and pressure on emergency services. The analysis found that ear, nose and throat, trauma and orthopaedics, gastroenterology, ophthalmology and gynaecology and obstetrics departments were consistently the specialist departments with the greatest number of patients not seen for the first time. 'That's a breakdown' As part of the Government's 10-year health plan, the NHS is expected to meet its target of carrying out 92 per cent of routine operations and appointments within 18 weeks by March 2029 – a target that has not been achieved for almost a decade. The latest figures show how challenging that target will be given an estimated one million of the three million unseen patients have already gone more than 18 weeks without receiving any care. 'If accurate, three million people are trapped in an invisible waiting-list crisis, stuck without basic diagnostic tests of first appointments while their conditions worsen,' Rachel Power, the chief executive of the Patients Association, told the Guardian. 'The scale is staggering, as nearly half of all patients on a waiting list haven't been seen by anyone. That's not a healthcare service; that's a breakdown. 'These aren't just statistics. They're people checking their phones daily for hospital calls that never come, unable to plan their lives while their symptoms deteriorate.' Last month it was found people of working age are making up a growing proportion of those on the NHS waiting list for treatment in England. Data tables published for the first time by NHS England also show people in the most deprived parts of the country are more likely to wait more than a year to start hospital treatment than those in the least deprived. The figures, analysed by the PA news agency, showed 56.1 per cent of those on the list at the end of June this year were of working age (defined as age 19 to 64), up from 55.8 per cent a year ago and 55 per cent in June 2022. At the same time, the proportion of people on the waiting list under the age of 19 has fallen, standing at 10.8 per cent in June this year, down from 11.2 per cent a year earlier and 11.9 per cent in June 2022. The proportion who are over 65 has remained broadly unchanged at around 33.1 per cent. People of working age are also more likely to have to wait more than a year to start treatment (three per cent of patients in this age group at the end of June) than those over 65 (two and half per cent). However, the proportion is the same as those under 19 (also three per cent). An NHS spokesman said: 'NHS staff have made significant progress in reducing waiting lists in the last year, which are down by more than 260,000 since June 2024. 'All patients are assessed by clinicians as they are added to waiting lists, and we will continue with our plan to improve waiting times for patients throughout the year.'
South Wales Argus
2 hours ago
- South Wales Argus
Over-the-counter medicines could fail for Brits due to DNA
The trial saw 2,200 adults undergo whole genome sequencing to analyse how their individual DNA responds to the likes of antibiotics and over-the-counter painkillers. A staggering 99% showed a genetic variant that affects their sensitivity to certain medicines. This could mean some drugs, including over-the-counter, everyday painkillers, antibiotics and other prescription medications, won't work for some people based on their individual DNA. DNA could stop over-the-counter medicines working for some Brits The blood test, part of Bupa's My Genomic Health scheme, also looked into their genetic risk of developing 36 preventable diseases, including cancers, heart conditions and type 2 diabetes. It found 91% of participants were found to be at risk of developing a disease with genetic and lifestyle risk factors, such as fatty liver disease, breast cancer and certain heart diseases. While 73% had multiple genetic variants that put them at raised risk of developing a condition that could be prevented or detected early, leading to better health outcomes, including the likes of high cholesterol, skin cancer and type 2 diabetes. Of the participants, 49% were found to be carriers of a genetic variant that could lead to a raised risk of a certain condition in future generations. How to get your own Medication Check Following the successful pilot, Medication Check can now be purchased through Bupa and will also be available to more than three million of its customers as part of its workplace health scheme. A saliva test will establish what medications are most likely to be effective, those with increased risk of adverse side effects, or ones that won't work for you at all. When to see your GP about cancer Dr Rebecca Rohrer, clinical innovation and genomics director for Bupa, said: 'We've long known that most medications only work for 30-50% of the population. 'However, this pilot has highlighted just how significantly individual genomes impact the effectiveness of medications in treating conditions. 'With more than half of us regularly taking a prescription medication and an increasing number affected by a chronic condition, it's crucial that people are prescribed the right medicine from the start, tailored to their unique genetic makeup. 'In the longer term, genomics is key to early detection and even preventing some illnesses altogether.' Today is World Lung Cancer Day. Contact your GP practice if you are experiencing any of these signs and symptoms of lung cancer. It's probably nothing serious, but early diagnosis and treatment can save lives. Find out more at — NHS (@NHSuk) August 1, 2025 After completing the at-home medication check, patients will be offered a GP consultation with the healthcare provider to review any medication identified in their genetic tests. It comes as Bupa is about to introduce two new products to its My Genomic Health suite later this year that will help to prevent or detect illness earlier. The DNA Health Check will give people early warning of an increased genetic risk of four different conditions - breast cancer, prostate cancer, type 2 diabetes and cardiovascular disease. While the Advanced DNA Health Check will combine insights from medication, disease risk, carrier status and traits, and will look at the genetic risk of developing conditions such as heart disease, metabolic disease and 10 types of cancer. Recommended reading: Carlos Jaureguizar, CEO for Bupa Global, India & UK, said: 'Whole genomic sequencing is fundamentally changing our approach to healthcare, pivoting from treatment to prevention. 'It has the power to become a health passport that people can reference throughout their lives. 'We firmly believe genomics is the path to health innovation and prevention, reducing the nation's health burden and giving people personalised knowledge of their own genomic profile to live well for longer.'
